G Agnelli1, H R Buller2, A Cohen3, A S Gallus4, T C Lee5, R Pak6, G E Raskob7, J I Weitz8, T Yamabe6. 1. Internal and Cardiovascular Medicine - Stroke Unit, University of Perugia, Perugia, Italy. 2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 3. Guy's and St Thomas Hospital's, King's College, London, UK. 4. Department of Haematology, SA Pathology at Flinders Medical Centre & Flinders University, Adelaide, Australia. 5. Pfizer Inc., New York, NY, USA. 6. Pfizer Inc., Groton, CT, USA. 7. College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 8. McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE). OBJECTIVE: To perform a subgroup analysis to compare the efficacy and safety of apixaban and enoxaparin followed by warfarin for the treatment of VTE in patients with cancer enrolled in AMPLIFY. PATIENTS/ METHODS:Patients with symptomatic VTE were randomized to a 6-month course of apixaban or enoxaparin followed by warfarin. The primary efficacy outcome and principal safety outcome were recurrent VTE or VTE-related death and major bleeding, respectively. RESULTS: Of the 5395 patients randomized, 169 (3.1%) had active cancer at baseline, and 365 (6.8%) had a history of cancer without active cancer at baseline. Among patients with active cancer, recurrent VTE occurred in 3.7% and 6.4% of evaluable patients in the apixaban and enoxaparin/warfarin groups, respectively (relative risk [RR] 0.56, 95% confidence interval [CI] 0.13-2.37); major bleeding occurred in 2.3% and 5.0% of evaluable patients, respectively (RR 0.45, 95% CI 0.08-2.46). Among patients with a history of cancer, recurrent VTE occurred in 1.1% and 6.3% of evaluable patients in the apixaban and enoxaparin/warfarin groups, respectively (RR 0.17, 95% CI 0.04-0.78); major bleeding occurred in 0.5% and 2.8% of treated patients, respectively (RR 0.20, 95% CI 0.02-1.65). CONCLUSIONS: The results of this subgroup analysis suggest that apixaban is a convenient option for cancer patients with VTE. However, additional studies are needed to confirm this concept and to compare apixaban with low molecular weight heparin in these patients.
RCT Entities:
BACKGROUND: The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE). OBJECTIVE: To perform a subgroup analysis to compare the efficacy and safety of apixaban and enoxaparin followed by warfarin for the treatment of VTE in patients with cancer enrolled in AMPLIFY. PATIENTS/ METHODS:Patients with symptomatic VTE were randomized to a 6-month course of apixaban or enoxaparin followed by warfarin. The primary efficacy outcome and principal safety outcome were recurrent VTE or VTE-related death and major bleeding, respectively. RESULTS: Of the 5395 patients randomized, 169 (3.1%) had active cancer at baseline, and 365 (6.8%) had a history of cancer without active cancer at baseline. Among patients with active cancer, recurrent VTE occurred in 3.7% and 6.4% of evaluable patients in the apixaban and enoxaparin/warfarin groups, respectively (relative risk [RR] 0.56, 95% confidence interval [CI] 0.13-2.37); major bleeding occurred in 2.3% and 5.0% of evaluable patients, respectively (RR 0.45, 95% CI 0.08-2.46). Among patients with a history of cancer, recurrent VTE occurred in 1.1% and 6.3% of evaluable patients in the apixaban and enoxaparin/warfarin groups, respectively (RR 0.17, 95% CI 0.04-0.78); major bleeding occurred in 0.5% and 2.8% of treated patients, respectively (RR 0.20, 95% CI 0.02-1.65). CONCLUSIONS: The results of this subgroup analysis suggest that apixaban is a convenient option for cancerpatients with VTE. However, additional studies are needed to confirm this concept and to compare apixaban with low molecular weight heparin in these patients.
Authors: Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young Journal: Oncologist Date: 2018-04-12
Authors: Majed S Al Yami; Hisham A Badreldin; Abdelhameed H Mohammed; Ahmed M Elmubark; Mohammed Y Alzahrani; Abdulmajeed M Alshehri Journal: J Thromb Thrombolysis Date: 2018-08 Impact factor: 2.300
Authors: A Franco-Moreno; L Cabezón-Gutiérrez; M Palka-Kotlowsa; M Villamayor-Delgado; M García-Navarro Journal: J Thromb Thrombolysis Date: 2019-04 Impact factor: 2.300
Authors: Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess Journal: Dtsch Arztebl Int Date: 2019-01-18 Impact factor: 5.594